The impact being in a pressurised aeroplane could have on your symptoms. Whether you have existing chest problems which could mean flying could make your symptoms worse.
People Also Ask
Patients with active or contagious chest infections should avoid traveling until they are no longer infectious, as they may infect those sitting next to them. Flying is usually possible 7 to 10 days after the infection, even though the cough and mucus can last up to 3 weeks.
The most important preventive measure is to avoid flying when symptoms of upper respiratory tract infection are present. When this is not possible, passengers should yawn, swallow, or chew to relieve pressure in the middle ear. Use of the Valsalva maneuver and decongestants or antihistamines may be helpful.
Persons with any of the following conditions should not travel by air: Pneumothorax (collapsed lung) within 2 to 3 weeks prior to travel. Pleural effusion (excess fluid occurring between the pleural layers) within 2 weeks prior to travel. Major chest surgery within 10 to 14 days prior to travel.
Pleurisy is an inflammation of the thin layers of tissue that cover the lungs and ribcage. It causes severe chest pain and difficulty breathing. Flying commercially while suffering from pleurisy is strongly discouraged. Pulmonary embolism and respiratory distress are the two most feared complications.
However, if the breathing rate is already accelerated due to pneumonia and the traveller is unable to take in enough oxygen, this situation, and thus the patient's condition, can deteriorate further.
An airline can deny boarding of any passenger who looks unwell, especially if they suspect the passenger might be infectious (infect other passengers).
Low air pressure during air travel also decreases the amount of oxygen in the air. This effect is modest and generally not noticeable for healthy travelers. For patients with significant lung disease, a small decrease in available oxygen can cause significant symptoms, especially with exercise.
Values >95% on room air suggest that inflight hypoxemia is unlikely and that further evaluation is likely not necessary. Patients with saturations <92% on room air at rest should receive supplemental oxygen inflight, because they are at high risk of hypoxemia at altitude.